Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Satish-Wagh"

14 News Found

Supriya Lifescience FY24 PAT up 32%
News | June 03, 2024

Supriya Lifescience FY24 PAT up 32%

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
News | February 09, 2024

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr
News | November 08, 2023

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D
People | May 27, 2023

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Merck names Miguel Alcalde to lead global commercial strategy; Monia Vial to head North America

Merck wins EU nod for KEYTRUDA-Padcev regimen in muscle-invasive bladder cancer

Reliance-backed Karkinos Healthcare crosses 1 lakh cervical cancer screening in India

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International

Packaging